DOP22: Antibiotic Use as a Risk Factor for Inflammatory Bowel Disease Across the Ages: A Population-Based Cohort StudyECCO’23 Copenhagen 2023
DOP23: Decrements in quality of life associated with symptoms of Inflammatory Bowel Disease: results from the UK IBD-BOOST surveyECCO’23 Copenhagen 2023
DOP24: Early life exposures and risk for inflammatory bowel disease: a nested case-control study in Quebec, CanadaECCO’23 Copenhagen 2023
DOP25: Contraceptive method use according to Inflammatory Bowel Disease status among young women in the United StatesECCO’23 Copenhagen 2023
DOP27: Disease activity patterns in the first 5 years after diagnosis in children with Crohn’s disease: a population-based study.ECCO’23 Copenhagen 2023
DOP28: Aconitate decarboxylase 1 (ACOD1) represents a crucial regulator of monocyte recruitment, survival and proinflammatory status in intestinal inflammationECCO’23 Copenhagen 2023
DOP29: Single cell analysis of Crohn’s disease fistula; comparison of different locationsECCO’23 Copenhagen 2023
DOP30: Identifying dietary factors and metabolites that may promote healthier Crohn Disease microbiome and mucosal transcriptomics signals as future targets using Diet-OmicsECCO’23 Copenhagen 2023
DOP31: Gut metabolomic and compositional signatures predict response to treatment with exclusive enteral nutrition in children with active Crohn’s diseaseECCO’23 Copenhagen 2023
DOP32: Crohn’s disease stricture matrisome analysis reveals the anti-fibrotic activity of milk-fat globule-epidermal growth factor 8 (MFGE8)ECCO’23 Copenhagen 2023
DOP33: Single-cell analysis identifies pathological fibroblasts as a new therapeutic target to prevent intestinal fibrosis in Crohn’s disease.ECCO’23 Copenhagen 2023
DOP34: Human MD2 deficiency - an inborn error of immunity predisposing to early onset Inflammatory Bowel DiseaseECCO’23 Copenhagen 2023
DOP35: High-fat diet reduces gut microbiota-derived metabolite indole-acetic acid and aggravates colitisECCO’23 Copenhagen 2023
DOP36: Vedolizumab-treated IBD patients show an increased gut microbial diversity associated with a specific serum metabolic signatureECCO’23 Copenhagen 2023
DOP37: Efficacy and safety of 3 years of continuous ozanimod treatment: an interim analysis of the True North open-label extension studyECCO’23 Copenhagen 2023
DOP38: Upadacitinib Therapy Reduces Crohn’s Disease Symptoms Within the First Week of Induction TherapyECCO’23 Copenhagen 2023
DOP39: Endoscopic, histologic, and combined outcomes with reinitiation of ozanimod after temporary discontinuation: 2-year interim analysis of the True North open-label extension studyECCO’23 Copenhagen 2023